

L.N. 199 of 2022

Dangerous Drugs Ordinance (Amendment of First Schedule) Order 2022

(Made by the Chief Executive under section 50(1) of the Dangerous Drugs Ordinance (Cap. 134) after consultation with the Executive Council)

1. Commencement

- (1) Subject to subsection (2), this Order comes into operation on 16 December 2022.
- (2) Section 3(2) comes into operation on 1 February 2023.

2. Dangerous Drugs Ordinance amended

The Dangerous Drugs Ordinance (Cap. 134) is amended as set out in section 3.

3. First Schedule amended

- (1) First Schedule, Part I, paragraph 1(a), after item “Bromazepam (溴西洋)”—

Add

“Brorphine (溴啡)”.

- (2) First Schedule, Part I, paragraph 1(a), after item “Camazepam (卡馬西洋)”—

Add

“Cannabidiol (大麻二酚)”.

- (3) First Schedule, Part I, paragraph 1(a), item “Clobazam (氯巴詹)”—

Repeal

“詹”

Substitute

“占”.

- (4) First Schedule, Part I, paragraph 1(a), after item “Clonazepam (氯硝西洋)”—

Add

“Clonazolam (氯氮唑侖)”.

- (5) First Schedule, Part I, paragraph 1(a), after item “Diazepam (安定)”—

Add

“Diclazepam (二氯西洋)”.

- (6) First Schedule, Part I, paragraph 1(a), item “Difenoxin (氟苯哌酸氰)”—

Repeal

“酸氰”

Substitute

“酸”.

- (7) First Schedule, Part I, paragraph 1(a), after item “Dioxaphetyl butyrate (嗎苯丁酯)”—

Add

“Diphenidine (二苯基乙基哌啶)”.

- (8) First Schedule, Part I, paragraph 1(a), after item “Flualprazolam (氟阿普唑侖)”—

Add

“Flubromazolam (氟溴唑侖)”.

- (9) First Schedule, Part I, paragraph 1(a), after item “Isomethadone (異美沙酮)”—

Add

“Isotonitazene (異硝氮烯)”.

- (10) First Schedule, Part I, paragraph 1(a), after item “Methyl N- {[1-(cyclohexylmethyl)-1H-indol-3-yl]carbonyl}-3-methylvalinate (N- {[1-(環己基甲基)-1H-吲哚-3-基]羰基}-3-甲基纈氨酸甲酯)”—

Add

“Methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate (3,3- 二甲基 -2-(1-(戊 -4- 烯 -1- 基)-1H- 吲唑 -3- 甲酰基) 丁酸甲酯)”.

- (11) First Schedule, Part I, paragraph 1(a), after item “Methyl phenidate (哌醋甲酯)”—

Add

“Metonitazene (甲硝苯)”.

- (12) First Schedule, Part I, paragraph 1(a)—

Repeal item “Nicocodine (6- 烟鹼可待因 (菸鹼可待因))”

Substitute

“Nicocodine (6-nicocodine) (菸鹼可待因 (6- 煙鹼可待因))”.

- (13) First Schedule, Part I, paragraph 1(a), item “Nicomorphine (3,6-dinicotinoyl-morphine) (3, 6 二烟酰嗎啡 (菸鹼嗎啡))”—

Repeal

“3, 6 二烟”

Substitute

“3,6 二煙”.

- (14) First Schedule, Part I, paragraph 1(a), item “Zipeprol (雙苯呱丙醇)”—

Repeal

“呱”

Substitute

“哌”.

- (15) First Schedule, Part I, paragraph 1(a), after item “4-Methylthioamphetamine (4-甲硫苯丙胺(4-甲硫安非他明))”—

Add

“5-Pentyl-2-(2-phenylpropan-2-yl)-2,5-dihydro-1H-pyrido[4,3-b]indol-1-one (5-戊基-2-(2-苯基丙-2-基)-2,5-二氢-1H-吡啶[4,3-b]吲哚-1-酮)”.

- (16) First Schedule, Part III, paragraph 19, item “Ethylmorphine (3-ethylmorphine) (乙基嗎啡)”, after “乙基嗎啡”—

Add

“(3-乙基嗎啡)”.

- (17) First Schedule, Part III, paragraph 19, item “Nicocodine (菸鹼可待因)”—

Repeal

“(菸鹼可待因)”

Substitute

“(6-nicocodine) (菸鹼可待因 (6-煙鹼可待因))”.

John KC LEE
Chief Executive

14 October 2022

Explanatory Note

This Order amends Part I of the First Schedule to the Dangerous Drugs Ordinance (Cap. 134) to—

- (a) bring 9 substances into the regulatory regime under the Ordinance as from 16 December 2022; and
 - (b) bring Cannabidiol into the regulatory regime under the Ordinance as from 1 February 2023.
2. The Order also amends Parts I and III of that Schedule to make technical amendments in respect of the names of substances specified in 7 items in those Parts.